Wednesday, February 22, 2012

Site Search

Archive for July, 2010

Exactive High Performance Benchtop LC-MS Mass Spectrometer

Thermo Scientific* Exactive Mass Spectrometer is an easy-to-use benchtop system combining premium performance with a simple, intuitive interface, resulting in a LC-MS system that is smaller, faster and affordable for virtually any lab.

The Exactive is the ideal benchtop LC-MS system for accurate, high-throughput screening and compound identification. It features high resolution, accurate mass and fast scanning capabilities which make it ideally suited for both screening and quantification of compounds in complex samples.
Designed for high-throughput and high-performance screening and compound identification applications, Exactive benchtop LC-MS system leverages the company?s proven Orbitrap* mass analyzer technology, the recognized standard for accurate mass and high-resolution measurement, to provide precise and reliable information. It is fast, easy to use, cost effective to operate and, coupled with workflow-driven software, makes an ideal instrument for new users in routine analytical laboratories.

  • Compound screening using high resolution accurate mass
  • “All Ion Fragmentation” for structural elucidation
  • Up to 100,000 resolution for complex sample analysis
  • Benchtop LC-MS with FTMS performance

The Thermo Scientific Exactive begins a new era in high resolution benchtop mass spectrometry for simple and complex sample screening. This easy-to-use LC-MS system delivers accurate mass for every scan without the need for data averaging. Operating at a 10 Hz scanning frequency Exactive is fully compatible with U-HPLC and ensures exact mass measurement for fast chromatography applications.

Powered by Orbitrap technology, the Exactive is ideal for compound identification and high throughput screening for both qualitative and quantitative analysis. The Exactive uses high resolution accurate mass to provide fast, reproducible, precise results — without compromise.

  • Streamlines many of the technical steps that normally require specialized setup and operation
  • Intuitive software interface makes the system easy to use in both expert and walk-up mode; ensures precise mass identification of target compounds over a wide concentration range
  • Sets new standards for LC-MS performance at resolutions of up to 100,000
  • Pathfinder software provides the right workflow for the right analysis, enabling experienced users to tune and optimize the system, develop methods and perform a wide range of experiments
  • New users and non-mass spectrometrists can easily follow developed methods to get analytical answers quickly and automatically
  • If necessary, both levels of users can then jointly utilize Pathfinder data review capabilitie

Set and forget using all resolution settings of up to 100,000, the Exactive is fully compatible with fast U-HPLC and delivers accurate mass information all the time — for every scan.

Simply use the system in default mode and select the required scan speed.

The key to faster, unambiguous results is high resolution and accurate mass

New software to calculate elemental compositions uses a special isotopic pattern and intensity algorithm to refine the list of potential candidates and, in most cases, delivers a single answer without pre-defining the set of elements. In combination with this intelligent software processing, the Exactive provides fully automated elemental compositions

source: thermoscientific.com

Using SPA to Screen Compressed Plates for Monoamine Receptor Ligands

Scintillation Proximity Assay technology (SPA) provides a homogeneous assay format that is useful for receptor ligand binding assays. The homogeneous nature eliminates the separation steps necessary for filtration assays and enables optimization for automated high-throughput drug screening. Applying this technology to 384-well plate formats has allowed researchers to further increase assay throughput. However, not every assay adapts well to higher density plate formats, so another means of increasing assay throughput is required. In these cases we propose that screening with compound mixtures, or ‘compressed plate screening’, is a useful alternative. Compressed plates are not new to the screening community, but the complexity of data analyzis and cumbersome follow-up investigations of primary hits have kept many researchers from using them(1,2). This article addresses these limitations including the issues of false positives and the preservation of assay sensitivity. Additionally, compressed plate generation using compression algorithms and the process of deconvolution for the purpose for data analyzis are discussed. We propose that compressed plate screening is feasible when primary hit rates are low (<1%) and when screening at low compound concentrations (1μM). Results indicated that more than 7-fold savings in time, money, and reagents after follow-up analyzis has been completed.

Compressed Plates

Testing mixtures of compounds in a well increases assay throughput, but a method for identifying active compounds from active mixtures is needed(3). Using an algorithm to ‘compress’ 96-well microtiter plates in a ‘self-deconvoluting’ fashion, generated compressed plates in an 8:1 format. The 8:1 compressed plate contained 720 unique test compounds (18 or 20 compounds per well) and is prepared from eight 96- well plates containing 90 compounds each.

To reduce the imbalance in the number of compounds per well on the destination plate, the eight 96-well compound plates are reformatted into 9 x 10 matrices. These matrices are aligned to make two 18 x 20 matrices, or two ‘source plates’ (one source plate is shown in Figure 1).

Figure 1. One source plate (18 x 20 matrix).

Compounds in each 18 x 20 matrix are then combined to make row mixtures and column mixtures; each destination plate would have 36 row mixtures and 40 column mixtures containing 18 or 20 compounds per well. Row mixtures from source plates 1 and 2 (S1 and S2) were dispensed into the upper half of the destination plate (18 row mixtures each: S1R1–S1R18 and S2R1-S2R18). S1 and S2 column mixtures were dispensed into the bottom half of the destination plate (20 column mixtures each: S1C1-S1C20 and S2C1-S2C20). Wells H7-H12 are reserved for controls (Figure 2).

Figure 2. 96-well destination plate containing compound mixtures.

Each compound was present on the destination plate in two mixtures: one row and one column mixture. Both mixtures are otherwise unique, so that a positive assay result in two such wells identified one and only one compound. For example, if mixtures in wells A3 and E7 in the assay plate above were identified as active, the deconvoluting algorithm identifies the source plate or 18 x 20 matrix in which the compound resides. The algorithm also identified the original compound plate and the putatively active compound (identified by the intersection of the row 3 column 7 mixtures, Figure 3). Deconvolution of hits using the matrix layout was time consuming and error prone, so software was developed to automate the process.

Figure 3. Intersection of active column and row mixtures identifies compound.

An active row mixture and column mixture from a source plate was needed to identify an active compound; the intersection of row and column ‘uniquely’ identifies it. When more than one row and column mixture on a plate are active an individual compound has not been identified (Figure 4a). Assume compounds B11 and C10 were true actives. Compound C9 was falsely declared active because it was in column 3 (an active mixture because of compound B11) and in row 4 (an active mixture because of compound C10). A similar scenario exists for compound B12. The deconvolution program reported that all 4 mixtures (R3, R4, C3, and C4) were active in the assay, but could not decipher which combination of active mixtures constituted this activity. Therefore there was a configuration artifact which generated false positives. All four compounds had to be retested and only half (compounds in B11 and C10) were confirmed. This scenario becomes more complex as hit rates increased (Figure 4b). For effective screening, primary hit rates for 8:1 compressed plates should be <1% and the plate to plate hit rate variability should also be low.

Figure 4a. Configuration dilemma leading to false positives.

Figure 4b. Computer simulation deriving the % of false positives generated with increasing hit rate in compressed plates.

In addition to false positives generated with increasing hit rates, the presence of several compounds in a mixture also increased the likelihood of additive, synergistic, or antagonistic interactions(2,3). Such interactions (in addition to pipetting errors) resulted in spurious hits, where a single row or column hit on a plate occurred without the corresponding column or row hit. In the absence of a correspondingly active mixture, this spuriously active well would not be flagged as a hit and would not need to be reconfirmed. The presence of several compounds in a mixture may reduce assay sensitivity, or the ability to identify an active compound within a mixture. Assay sensitivity was tested using 76 mixtures from an 8:1 compressed plate library using a receptor binding assay for serotonergic 5-HT2C ligands (Figure 5). Hits were identified as compounds producing >50% inhibition of specific radioligand binding(4). However, each of the 76 mixtures gave <50% inhibition in the assay and would not have been flagged as active in a screen. Mixtures were then spiked with 5-HT2C ligands of varying affinity; MK212, mCPP, or metergoline(5). In each of the inactive compound mixtures, these ligands were detectable, indicating that unknown mixtures do not adversely affect assay sensitivity. Additionally, the assay was able to distinguish between low, moderate, and high responses with compounds of varying affinity. Similar results were obtained using serotonergic 5-HT7 and dopaminergic D4 receptor binding assays (data not shown).

Figure 5. Measure of SPA 5-HT2C receptor binding assay sensitivity.

Following compressed plate SPA assay development and validation, a screen was conducted for serotonergic 5-HT2C ligands. Hits were identified as compounds producing >50% inhibition of specific radioligand binding. Fresh samples of these putative actives were obtained and tested individually. Confirmed active compounds were further evaluated for potency and receptor selectivity.

Results

Primary Screen

  • 107,644 compounds were screened
  • 88,744 compounds were screened in 8:1 compressed plates
  • 18,900 compounds were screened in singleton plates (new compound acquisitions were not available in compressed plate format) Primary/Putative Hits
  • 862 primary actives were identified (0.8% primary hit rate)
  • 752 primary actives from compressed plates (0.8% compressed plate primary hit rate)
  • 110 primary actives from singleton plates (0.6% singleton plate primary hit rate)

Confirmed Hits

  • 369 compounds confirmed as actives (43% confirmation rate)
  • 269 confirmed compressed plate hits (36% compressed plate confirmation rate)
  • 100 confirmed singleton plate hits (91% singleton plate confirmation rate)

Final Hit Rate

  • Overall confirmed hit rate for the screen: 0.3%e
  • Overall compressed plate hit rate: 0.3%
  • Overall singleton plate hit rate: 0.5%

The 36% confirmation rate for primary actives in compressed plates seems remarkably low in comparison to the 91% confirmation rate for hits identified in singleton plates. Later screens for serotonergic 5-HT7 ligands and dopaminergic D4 ligands revealed similar hit rates for compressed and singleton plate sets.

The low compressed plate confirmation rates resulted from the complexity of the plate configuration and the deconvolution process. The computer simulation in Figure 4b illustrated the relationship between hit rates and false positives; the 0.8% primary hit rate in the 5-HT2C screen generated the predicted number of false positives.

Although 862 putative actives had to be retested in order to confirm 369 active compounds, compressed plates still provided considerable savings in time and money. The primary screening and confirmation of hits from the 88,744 compounds tested in compressed plates required 164 assay plates. In singleton plate format, 986 plates would have been required to assay the same compounds. This reflects better than 7-fold savings in time, reagents, plates, and compounds for assays using 8:1 compressed plates.

With primary hit rates of <1%, follow-up and data analyzis were manageable. Compounds discovered in the screen can not yet be disclosed, the identification of several known commercial 5-HT2C ligands in this assay (Table 1) further validates the feasibility of screening successfully with compressed plates.

Chlorpromazine Amitriptyline
Chlorprothixene Serotonin
Cinanserin Clopenthixol
Cyproheptadine Nortriptyline
Lisuride Triflupromazine
MCPP Melitracen
Methotrimeprazine
Methysergide BP-400
Oxymetazoline Doxepine
Trimeprazine Prochlorperazine
Trimipramine Phenyltoloxamine

Table 1. Known compounds identified in the 5-HT2C SPA screen.

Conclusions

Testing compounds as mixtures in SPA receptor binding assays can dramatically reduce screening effort.

Additionally 8:1 compressed plate formats can further reduce screening effort by more than 7-fold when screening at low compound concentrations, when compound mixtures do not adversely affect assay sensitivity, and when hit rates are low. The deconvolution program identified false positives due to complexity of the compressed plate format, therefore all putative hits from mixtures had to be confirmed as singletons. It worked well when hit rates and plate to plate variability are low, such that the complexity of analyzis and follow-up were manageable. Although confirmation rates are likely to be much lower for compressed plate hits than those identified in singleton plates, the savings achieved via combination of SPA technology and compressed plate formats are substantial. Compressed plates can therefore provide an excellent format for increasing assay throughput when assays are not easily adaptable to higher density plate formats.

Source: las.perkinelmer.com

New Study Shows How Worms Can Help Screen For New Drugs

The humble nematode worm could prove of inestimable in screening new compounds on account of active drugs, chic enquiry published today suggests.

Soil-homestead nematodes have a programmed avoidance response to harmful chemicals, which they detect from one end to the other nerves exposed to their conditions. Scientists led by the Wellcome Sureness Sanger Start possess genetically modified the worm C. elegans to make human proteins called receptors in these nerves: the modified worms detect and steer clear of human signalling molecules and soporific candidates.

The exciting results, reported today, 20 July 2006, in the untaken receptive-access journal BMC Biology, promise a simple assay that can be acquainted with to interview thousands of compounds for vim against human proteins – a foundation of drug event.

“The worm is a great tool to understand biology,” said Dr Michelle Teng of the Wellcome Assurance Sanger Alliance, a lead author on the discharge. “Because we understand it so well – it has a undesigning doubtlessly studied in a tizzy set-up – the role on account of each nerve has been mapped in detail. We also would rather a good truce of the signalling mechanisms in nerves that drive the responses.

“We showed that the biochemical response of the receptors emulated that seen in humans. It is very recently that, in the worm, the effects of that response are to make them toady away from the chemical stimulus. This forthright response could be adapted to to test many unknown medicine candidates.”

Medicines continually interact with receptors, which are “sensors” at the show up of cells. The crew introduced the somatostatin receptor (Sstr2) and the chemokine receptor 5 (CCR5) in the nerves that touched by to environmental cues. Somatostatin is a hormone that mediates a wide sphere of activities in humans and chemokines play an important situation in the immune system. The CCR5 receptor used is also the gateway that HIV/AIDS virus uses to set cells. Both receptors belong to a receptor family called GPCRs, which pretend to be up to 50% of current opiate targets.

The response was specific. In tests, worms responded by avoiding somatostatin or chemokine placed in their paths alone when the pertinent receptor was made in the appropriate nerves.

“We have shown that we can hijack the cellular machinery of the worm so that the man receptor proteins drive the avoidance response,” explained Dr John McCafferty, Principal Investigator at the Wellcome Trust Sanger Institute and senior author. “We chose two receptors with to a large differing functions in humans. The responses were personal to to the compounds we added and could be inhibited in the same way a effect in humans could be restrained.”

The worms could also be desensitized by pre-exposure to somatostatin or chemokine: desensitization is an important have a share of normal philanthropist response, because it ensures that our receptors can recover repayment for a fresh volley of stimulus. This is the cardinal over and over again that activation has been programmed in these nerves and the team have shown that the human receptors integrate into the worm signalling machinery.

“Systems exist already to study the response of cells in evaluation-tubes to added compounds,” continued Dr McCafferty. “However, because these are ground-dwelling worms which supply on bacteria, we could evaluate crude samples for the purpose antidepressant candidates. Together, these results make us very optimistic that these models longing be widely apt and that development of a boisterous-throughput system is practical.”

The span used a instantaneous sorting system to isolate the genetically modified worms. Although, for this swat, worm responses were scored below the microscope, automation could be integrated to achieve a higher rate of testing.

The worm model can also alleviate to define which regions of a novel compound are foremost due to the fact that its biological effect, which can be crucial in compensation producing noticeable drugs. The conspire were able to usefulness the worm assay to identify four superior building blocks within the somatostatin molecule which are known to be necessary in the interest of its make.

“These results show the power of oafish organisms such as the worm to help us not only in our understanding of biology but also in the search for untrained ways to improve healthcare,” said Professor Ronald Plasterk, Professor of Developmental Genetics at the University of Utrecht and Director of the Hubrecht Laboratory, in the Netherlands. “It is a comfortably irony of history that the worm was chosen for biomedical examination by Sydney Brenner forty years ago in Cambridge, sole a not many miles from the Sanger Institute. Then twenty years ago John Sulston started to make a gene map of the animal, and long run read its sequence as the elementary of all animal genomes.

“And infrequently a new generation of researchers again in the Cambridge area uses it to test office-seeker drugs that are immediately relevant to sympathetic vigorousness.”

Publication details
Teng MS et al. (2006) Face of mammalian GPCRs in C. elegans generates novel behavioural responses to human ligands. BMC Biology 4:22 doi:10.1186/1741-7007-4-22

The publication, which is available able of charge, according to BioMed Central’s into operation-access policy, is at: http://www.biomedcentral.com/1741-7007/4/22.

The BMC Biology website is http://www.biomedcentral.com/bmcbiol.

Participating Centres and websites

Wellcome Confidence in Sanger Institute – C. elegans lab:

http://www.sanger.ac.uk/Teams/Team37

Wellcome Trust Sanger Institute – ATLAS Engagement:

http://www.sanger.ac.uk/Teams/Team86

Erasmus Medical Concentrate – Jansen lab:

http://www2.eur.nl/fgg/ch1/cellbiology/jansen

The Wellcome Trust Sanger Initiate, which receives the majority of its funding from the Wellcome Trust, was founded in 1992 as the centre for UK sequencing efforts. The Institute is responsible suited for the completion of the sequence of approximately one-third of the human genome as equably as genomes of version organisms such as mouse and zebrafish, and more than 90 pathogen genomes. In October 2006, further funding was awarded by the Wellcome Empower to enable the Institute to build on its on cloud nine-class systematic achievements and turn to account the bounty of genome data now available to answer important questions connected with health and disease. These programmes are built surrounding a Faculty of more than 30 higher- ranking researchers. The Wellcome Sureness Sanger Association is based in Hinxton, Cambridge, UK.

http://www.sanger.ac.uk

The Wellcome Trust is the most diverse biomedical fact-finding generosity in the world, spending adjacent to £450 million every year both in the UK and internationally to support and plug delving that will improve the health of humans and animals. The Credit was established impaired the will of Sir Henry Wellcome, and is funded from a unsociable allowance, which is managed with sustained-length of time stability and crop in rail at.

Wellcome Trust Sanger Institute
Hinxton, Cambs, CB10 1SA, UK

http://www.sanger.ac.uk

source: abundanttanzania.qanka.biz

GSK and Online Communities Create Unique Alliance to Stimulate Open Source Drug Discovery for Malaria

- GSK becomes first company to freely share chemical structures on 13,500 molecules from its compound library
- Alliances formed with leading scientific research communities from private industry and public-domain data provider
Logos
May 19, 2010/Burlingame, CA/ GlaxoSmithKline (GSK) had teamed up with leading public-domain data providers European Bioinformatics Institute (EMBL-EBI), the U.S. National Library of Medicine (NLM) and the US-based informatics service provider Collaborative Drug Discovery (CDD) to make freely available key scientific information on more than 13,500 compounds that could ultimately lead to new treatments for malaria. 

The release of this data marks the first time that a pharmaceutical company has made available the structures of so many compounds and is made possible through the collaboration of the web hosts and their specialist research tools, which will be available at no cost to researchers. The information, which is hosted on websites regularly used by researchers, includes high quality scientific data about the molecules from GSK’s own compound library which have demonstrated potency against the most deadly malaria parasite, P. falciparum. 

“We are delighted that EMBL-EBI, NLM and CDD have joined us in this worthwhile endeavour to apply the principles of open source to drug discovery for malaria,” said Patrick Vallance, head of drug discovery at GSK. “Defeating this disease will require many scientific minds working together. We hope researchers from across the world will now use this information to drive further studies, and that other groups from pharmaceutical industry to academia will add their information to this on-line resource.” 

This type of data is the first step on the road to developing new medicines. With the structure of the compounds and information about where they affect the malaria parasite, scientists could then carry out further research on these compounds for drug discovery or to understand how these might be used to inhibit the parasite’s life cycle and ultimately lead to new medicines. Opening up this information widely is essentially an example of ‘open source’ tactic being applied to drug discovery. 

“Making life-science information openly available to the research community is at the heart of the EMBL-EBI’s mission,” added John Overington, leader of the EMBL-EBI’s ChEMBL team, which will act as the primary repository for the data through its ChEMBL resource. “We’re proud to be able to add value to the GSK data by incorporating it into ChEMBL and linking it with a vast array of information that could help researchers to find new treatments for malaria. This is the beginning of a new era of public–private collaboration in drug research.”

“NLM is excited to be involved in this groundbreaking release of information to the public,” said Steve Bryant, head of NLM’s PubChem database, which is housing the data. “By making these data available through public resources such as PubChem, GSK is greatly facilitating the research process, as the information is linked to related compounds, bioactivity results, published literature, and other resources that will assist researchers in making new discoveries to combat malaria.”  

“CDD is delighted to be playing a role in this truly historic event,” commented Barry A. Bunin, CEO of Collaborative Drug Discovery. “In decades of medical breakthroughs from Big Pharmas, this is the first time a group is openly sharing all the chemical and biological data – not just the few hits.  Furthermore, for phenotypic screens, the CDD tools allow researchers to begin to hypothesize and validate the targets from the whole cell screens.” 

EMBL-EBI will act as the primary repository for the data on this compound set, and will index and format further information that is contributed. GSK will add more information as it is generated and external scientists researching these compounds and the data will be asked do the same. 

About the data

The data contains the ‘hits’ or results from a screening of the 2 million compounds in GSK’s compound library to determine the effect of these compounds on the malaria parasite. The screening project identified ~13,500 compounds that showed strong inhibition on the parasite.

Kinase inhibitors constituted a large proportion of the molecules with previously known activity and now identified as antimalarial hits. The data includes the chemical families that GSK is currently researching for this indication and the ‘mechanisms of action’ for those compounds which the company has previously tested for other indications.

Most of the compound structures identified have been classified as capable of being converted into medicine.

The current microbiological information for the compounds and the structures have been put on online resources that are easily accessed by researchers. The EMBL-EBI site has been constructed so that scientists globally can add their data to the information there, with access free to all. The value of the release of information is enhanced by the collaboration of the web hosts and the specialist research tools on the site, that are being made available to researchers at no cost to them.

GSK gratefully recognises the support of Medicines for Malaria Venture, which contributed funding for this project.

Full information can be viewed online at:

www.ebi.ac.uk/chembl/

http://pubchem.ncbi.nlm.nih.gov/

www.collaborativedrug.com/

About malaria

Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected mosquitoes. A child dies of malaria every 30 seconds. There were 243 million cases of malaria in 2009, causing nearly one million deaths, mostly among African children. 

The best available treatment for malaria – particularly the most deadly strain P. falciparum -  is a combination of drugs known as artemisinin-based combination therapies (ACTs). However, parasite resistance is an issue and is undermining malaria control efforts. There are no effective alternatives to artemisinins for the treatment of malaria either on the market or nearing the end of the drug development process.

About GlaxoSmithKline

GlaxoSmithKline –  one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For more information about GSK, visit www.gsk.com 

About the European Bioinformatics Institute (EMBL-EBI)

The European Bioinformatics Institute (EMBL-EBI) is part of the European Molecular Biology Laboratory (EMBL) and is located on the Wellcome Trust Genome Campus in Hinxton near Cambridge (UK). The EMBL-EBI grew out of EMBL’s pioneering work in providing public biological databases to the research community. It hosts some of the world’s most important collections of biological data, including DNA sequences (ENA), protein sequences (UniProt), animal genomes (Ensembl), three-dimensional structures (the Protein Databank in Europe), data from gene expression experiments (ArrayExpress), protein-protein interactions (IntAct) and pathway information (Reactome). The EMBL-EBI hosts several research groups and its scientists continually develop new tools for the biocomputing community.  For more information about EMBL-EBI, visit www.ebi.ac.uk 

About the National Library of Medicine (NLM)

The National Library of Medicine (http://www.nlm.nih.gov/) is the world’s largest library of the health sciences. NLM is a part of the National Institutes of Health (NIH), a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

Neuronetrix’ COGNISIONâ„¢ System

Alzheimer’s disease is a chronic neurodegenerative disease of the brain which afflicts roughly 5 million individuals in the United States.  Approximately 10% of those over 65 and 50% of those over 85 will die as a result of Alzheimer’s disease.

Even with several therapies available to treat Alzheimer’s disease, there still is a significant gap between the onset of the disease and point at which treatment actually begins.  This treatment gap is directly tied to the challenges in diagnosing the disease early, before the significant loss of memory, cognition, and activities of daily living.  Patients, doctors, caregivers, and the pharmaceutical industry, are looking for and demanding a solution to this problem.

Neuronetrix’ COGNISIONâ„¢ System will, for the first time, directly detect the abnormal cognitive effects of Alzheimer’s disease!  This will facilitate an earlier and more accurate diagnosis than is currently available.  Physicians will use the COGNISIONâ„¢ test to determine which patients would benefit from the available drug treatments.  The system can also be used to monitor the efficacy of the prescribed therapy.

With the aging of America and the proliferation of new Alzheimer’s therapies, the market for Alzheimer’s screening could approach several billion dollars per year in the United States alone.

Following the validation of the COGNISION™ System for Alzheimer’s disease, Neuronetrix will expand into other neurodiagnostic markets such as ADHD, dyslexia, and depression.

http://www.neuronetrix.com/